198 related articles for article (PubMed ID: 38773982)
21. Engineered CD47 protects T cells for enhanced antitumour immunity.
Yamada-Hunter SA; Theruvath J; McIntosh BJ; Freitas KA; Lin F; Radosevich MT; Leruste A; Dhingra S; Martinez-Velez N; Xu P; Huang J; Delaidelli A; Desai MH; Good Z; Polak R; May A; Labanieh L; Bjelajac J; Murty T; Ehlinger Z; Mount CW; Chen Y; Heitzeneder S; Marjon KD; Banuelos A; Khan O; Wasserman SL; Spiegel JY; Fernandez-Pol S; Kuo CJ; Sorensen PH; Monje M; Majzner RG; Weissman IL; Sahaf B; Sotillo E; Cochran JR; Mackall CL
Nature; 2024 Jun; 630(8016):457-465. PubMed ID: 38750365
[TBL] [Abstract][Full Text] [Related]
22. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
[TBL] [Abstract][Full Text] [Related]
23. ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.
Li L; Gong Y; Tang J; Yan C; Li L; Peng W; Cheng Z; Yu R; Xiang Q; Deng C; Mu J; Xia J; Luo X; Wu Y; Xiang T
Cell Mol Life Sci; 2022 Jan; 79(2):83. PubMed ID: 35048182
[TBL] [Abstract][Full Text] [Related]
24. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
25. Understanding the regulation of "Don't Eat-Me" signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy.
Karizak AZ; Salmasi Z; Gheibihayat SM; Asadi M; Ghasemi Y; Tajbakhsh A; Savardashtaki A
J Cancer Res Clin Oncol; 2023 Jan; 149(1):511-529. PubMed ID: 36342520
[TBL] [Abstract][Full Text] [Related]
26. Combined strategies for effective cancer immunotherapy with a novel anti-CD47 monoclonal antibody.
Ni H; Cao L; Wu Z; Wang L; Zhou S; Guo X; Gao Y; Jing H; Wu M; Liu Y; Ding J; Zhang P; Zhou Y; Chen B; Xiong Y; Sun J; Prinz B; Baruah H; Geoghegan J; Yu M; Wu W; Liu J
Cancer Immunol Immunother; 2022 Feb; 71(2):353-363. PubMed ID: 34165607
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
[TBL] [Abstract][Full Text] [Related]
28. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
[TBL] [Abstract][Full Text] [Related]
29. Supermolecular nanovehicles co-delivering TLR7/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy.
Shang T; Yu X; Gu Y; Du R; Cai Y; Li Y; Zheng G; Wang C; Zhang J; Liu J; Han S; Yang B
Int J Biol Macromol; 2023 Nov; 251():126539. PubMed ID: 37634787
[TBL] [Abstract][Full Text] [Related]
30. CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.
Michaels AD; Newhook TE; Adair SJ; Morioka S; Goudreau BJ; Nagdas S; Mullen MG; Persily JB; Bullock TNJ; Slingluff CL; Ravichandran KS; Parsons JT; Bauer TW
Clin Cancer Res; 2018 Mar; 24(6):1415-1425. PubMed ID: 29288236
[No Abstract] [Full Text] [Related]
31. The regulation of CD47-SIRPα signaling axis by microRNAs in combination with conventional cytotoxic drugs together with the help of nano-delivery: a choice for therapy?
Beizavi Z; Gheibihayat SM; Moghadasian H; Zare H; Yeganeh BS; Askari H; Vakili S; Tajbakhsh A; Savardashtaki A
Mol Biol Rep; 2021 Jul; 48(7):5707-5722. PubMed ID: 34275112
[TBL] [Abstract][Full Text] [Related]
32. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy.
Cao A; Yi J; Tang X; Szeto CW; Wu R; Wan B; Fang X; Li S; Wang L; Wang L; Li J; Ye Q; Huang T; Hsu K; Kabbarah O; Zhou H
Cancer Res Commun; 2022 Nov; 2(11):1404-1417. PubMed ID: 36970051
[TBL] [Abstract][Full Text] [Related]
33. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
[TBL] [Abstract][Full Text] [Related]
34. Macrophage-associated immune checkpoint CD47 blocking ameliorates endometriosis.
Li J; Yan S; Li Q; Huang Y; Ji M; Jiao X; Yuan M; Wang G
Mol Hum Reprod; 2022 Apr; 28(5):. PubMed ID: 35404426
[TBL] [Abstract][Full Text] [Related]
35. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors.
Liu Y; Xue R; Duan X; Shang X; Wang M; Wang F; Zhu L; Zhang L; Ge X; Zhao X; Guo H; Wang Z; Zhang L; Gao X; Shen A; Sheng Y; Qin Z
Life Sci; 2023 Aug; 326():121790. PubMed ID: 37211345
[TBL] [Abstract][Full Text] [Related]
36. Exosome-SIRPα, a CD47 blockade increases cancer cell phagocytosis.
Koh E; Lee EJ; Nam GH; Hong Y; Cho E; Yang Y; Kim IS
Biomaterials; 2017 Mar; 121():121-129. PubMed ID: 28086180
[TBL] [Abstract][Full Text] [Related]
37. An Acquired and Endogenous Glycocalyx Forms a Bidirectional "Don't Eat" and "Don't Eat Me" Barrier to Phagocytosis.
Imbert PRC; Saric A; Pedram K; Bertozzi CR; Grinstein S; Freeman SA
Curr Biol; 2021 Jan; 31(1):77-89.e5. PubMed ID: 33096038
[TBL] [Abstract][Full Text] [Related]
38. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
[TBL] [Abstract][Full Text] [Related]
39. Galectin-3 Cooperates with CD47 to Suppress Phagocytosis and T-cell Immunity in Gastric Cancer Peritoneal Metastases.
Fan Y; Song S; Li Y; Dhar SS; Jin J; Yoshimura K; Yao X; Wang R; Scott AW; Pizzi MP; Wu J; Ma L; Calin GA; Hanash S; Wang L; Curran M; Ajani JA
Cancer Res; 2023 Nov; 83(22):3726-3738. PubMed ID: 37738407
[TBL] [Abstract][Full Text] [Related]
40. Engineered Biomimetic Copper Sulfide Nanozyme Mediates "Don't Eat Me" Signaling for Photothermal and Chemodynamic Precision Therapies of Breast Cancer.
Zhan Z; Zeng W; Liu J; Zhang L; Cao Y; Li P; Ran H; Wang Z
ACS Appl Mater Interfaces; 2023 May; 15(20):24071-24083. PubMed ID: 37159843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
